Article:Body mass index and risk of diabetic retinopathy: A meta-analysis and systematic review. (5459694)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q33765398. Its title is Body mass index and risk of diabetic retinopathy: A meta-analysis and systematic review. and the publication date was 2017-06-01. The initial author is Yue Zhou.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Medicine

Body mass index and risk of diabetic retinopathy

A meta-analysis and systematic review
  • Yue Zhou
  • Yuezhi Zhang
  • Ke Shi
  • Changyun Wang
  • Adebowale Adesina.

Department of Ophthalmology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Publication date (collection): 6/2017

Publication date (epub): 6/2017

Abstract

Abstract

Diabetic retinopathy (DR) is a frequent cause of acquired blindness worldwide. Various studies have reported the effects of body mass index (BMI) on the risk of DR, but the results remain controversial. Therefore, a meta-analysis was performed to evaluate the relationship between BMI and the risk of DR.

A systematic search was performed using the Cochrane Library, PubMed, and Embase databases to obtain articles published through December 2016. Articles regarding the association between BMI and the risk of DR were retrieved. The adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were included and then pooled with a random effects model.

A total of 27 articles were included in this meta-analysis. When BMI was analyzed as a categorical variable, neither being overweight (OR = 0.89, 95% CI 0.75–1.07; P = .21; I2 = 65%) nor obesity (OR = 0.97, 95% CI 0.73–1.30; P = .86) were associated with an increased risk of DR when compared with normal weight. When BMI was analyzed as a continuous variable, a higher BMI was not associated with an increased risk of DR (OR = 0.99, 95% CI 0.97–1.01; P = .25; I2 = 79%). The pooled results did not significantly change after the sensitivity analysis.

Based on the current publications, neither being overweight nor obesity is associated with an increased risk of DR. Further studies should confirm these findings.

Paper

Introduction

1

Diabetic retinopathy (DR), the most common visual complication of diabetes, is a frequent cause of acquired blindness. In 2010, it was reported that nearly 285 million people worldwide had been plagued with diabetes, of which over one-third had signs of DR.[[1]] Recent epidemiological studies have identified that the duration of diabetes, blood pressure, and glycemic control are several key risk factors for the development of DR.[[2]] However, evidence from the Action to Control Cardiovascular Risk in Diabetes (ACCORD-Eye) and Action in Diabetes and Vascular Disease (ADVANCE) revealed that limited effects had been obtained despite better glucose and blood pressure control.[[3],[4]] Thus, exploring modifiable risk factors has become increasingly important.

Body mass index (BMI), the most commonly used index of body mass, is calculated by dividing the weight in kilograms by the square of the height in meters.[[5]] According to the World Health Organization BMI classification system, BMI is categorized into the following four grades: underweight (<18.5 kg/m2), normal weight (18.5 kg/m2–24.9 kg/m2), overweight (25.0 kg/m2–29.9 kg/m2), and obese (≥30.0 kg/m2). It has been shown that being overweight and obesity are 2 risk factors for diabetes mellitus.[[6]] Thus, overweight and obese people are more vulnerable to DR. However, the results from previous studies were equivocal, with some studies[[7][9]] observing a decreased incidence of DR in higher BMI individuals, while other studies[[10][13]] detected a null association between high BMI and the incidence of DR. Moreover, other studies[[14],[15]] demonstrated that a significant decrease in glycated hemoglobin (HbA1c) and a significant increase in high-density lipoprotein cholesterol (HDL-C) and blood pressure were observed in higher BMI individuals, all of which are the risk factors for DR. Motivated by these equivocal results, we conducted a meta-analysis to assess the association between BMI and the risk of DR.

Methods

2

In performing this meta-analysis, we adhered to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines.[[16]] No ethical approval was warranted since it was a meta-analysis of available studies.

Literature search and study selection

2.1

We electronically searched the Cochrane Library, PubMed, and Embase databases up to December 2016 for articles evaluating the effects of BMI on DR in patients with type 1 or type 2 diabetes. The key words related to body mass (“body mass index” or “body mass” or “BMI” or “body weight” or “obesity” or “overweight’” or “adiposity”) and “diabetic retinopathy” were used to search for the relevant articles published in English. Moreover, reference lists and conference abstracts were also examined to retrieve potential relevant studies.

Studies were included if they fulfilled the following criteria: (a) observational study type; (b) participants with type 1 or 2 diabetes or both; (c) outcomes included DR; and (d) BMI was analyzed as a categorical or continuous variable. The categorical levels of BMI were assessed according to the WHO-recommended BMI classifications.[[17]] BMI levels within 2 kg/m2 of standard categories were also considered to be acceptable in case losing studies were available. The exclusion criteria were as follows: (a) the adjusted risk estimates were unavailable; (b) certain publication types (e.g., reviews, letters, case reports, comments, conference abstracts, and editorials); and (c) studies with duplicate or insufficient data.

Data extraction and quality assessment

2.2

Two reviewers (Z-Y and Z-YZ) independently screened all the identified articles, and any disagreements were resolved through discussion or through a consultation with the senior researcher (W-CY). For the included studies, the basic characteristics including the first author, publication year, study location, age range, design of study, sample size, diagnostic basis, grading standard, and the outcome were extracted. Additionally, if one study had several risk estimates (e.g., different periods of follow-up or different multivariate statistical analysis models), the risk estimate with the longest follow-up or the estimate that was most completely adjusted was extracted.

The Newcastle–Ottawa scale (NOS) score was used to evaluate the quality of the observational studies,[[18],[19]] which gave with a maximum score of 9 for the cohort or case-control study, and 8 for the cross-sectional study. NOS scores of 0–3, 4–6, and ≥7 were defined as low, moderate, and high quality, respectively.

Statistical analysis

2.3

All the statistical analyses were completed with the Revman Manager 5.3 (the Nordic Cochrane Center, Rigshospitalet, Denmark; http://ims.cochrane.org/revman). We assessed the association between BMI and the risk of DR when BMI was analyzed as a categorical or continuous variable. For each study, the adjusted odds ratio (OR) and its 95% confidence interval (CI) were regarded as the common risk estimate and pooled by the random-effects model with inverse variance weighting. The random-effects model was more conservative and could provide better estimates with wider confidence intervals than the fixed-effect model for any heterogeneity.[[20]] The consistency of included studies was evaluated using the Cochrane Q test complemented with I2 values, where I2 values <25% indicated no heterogeneity, 25%≤I2<50% indicated low heterogeneity, 50%≤I2<75% indicated moderate heterogeneity, and I2≥75% indicated high heterogeneity. In view of the heterogeneity among the included studies, we performed a sensitivity analysis by removing the included articles one by one. A funnel plot was used to assess the publication bias when more than 10 studies were included. In the presence of potential publication bias, visual asymmetry would be observed in the funnel plot.

Results

3

Study selection

3.1

As shown in Fig. 1, a total of 1544 articles were initially identified the Cochrane Library (n = 34), PubMed (n = 572), and Embase (n = 938) databases, of which 836 duplicate articles were removed. Among the remaining 708 articles, we excluded another 672 articles after screening the titles and abstracts. The potential 36 relevant articles thoroughly assessed for eligibility, and 9 of them were excluded for different reasons. Two articles[[10],[12]] calculated the total effect of overweight and obesity together instead of their separate effects. A case-control study[[13]] only reported the unadjusted ORs at a 95% CI. Two studies[[21],[22]] treated the nonobese group as the control. Four studies[[23][25],[57]] did not adhere to the BMI classification we adopted. Finally, 27 articles[[7],[26][51]] were included in this meta-analysis. All of the basic characteristics and the reporting qualities of the included studies are shown in Table 1.

Figure 1

Overview of the research strategy. BMI = body mass index, OR = odds ratio.

Table 1

Characteristics of the 27 included studies in this meta-analysis.

Meta-analysis of BMI and DR

3.2

When BMI was analyzed as a categorical variable, 6 studies compared the risk of DR between ‘overweight or obese BMI’ and ‘normal BMI.’ As shown in Fig. 2, neither being overweight (OR = 0.89, 95% CI 0.75–1.07; P = .21; I2 = 65%) nor obesity (OR = 0.97, 95% CI 0.73–1.30; P = .86; I2 = 72%) were associated with an increased risk of DR when compared with normal weight. When BMI was analyzed as a continuous variable, 23 studies reported an association between BMI and the risk of DR. As shown in Fig. 3, a higher BMI was not associated with an increased risk of DR (OR = 0.99, 95% CI 0.97–1.01; P = .25; I2 = 79%). In view of the heterogeneity among the included studies, we performed a sensitivity analysis to explore the source of heterogeneity. After we removed the included articles one by one, the I2 values were still more than 50%, which indicated moderate-high heterogeneity. However, the sensitivity analysis demonstrated that the stability of the overall treatment effects was good.

Figure 2

Forest plot for the association between BMI and the risk of DR when BMI was analyzed as a categorical variable. BMI = body mass index, CI = confidence interval, DR = diabetic retinopathy, SE = standard error.

Figure 3

Forest plot for the association between BMI and the risk of DR when BMI was analyzed as a continuous variable. BMI = body mass index, DR = diabetic retinopathy, SE = standard error, CI = confidence interval.

Publication bias

3.3

As shown in Fig. 4, the largest studies plotted near the average and the smaller studies were spread evenly on both sides of the average, indicating that a possible absence of publication bias was observed when the BMI was analyzed as a continuous variable. However, when BMI was analyzed as a categorical variable, only 6 studies were included. We therefore did not display the funnel plot in this part, as the analyses are likely underpowered.

Figure 4

Funnel plot of all the included studies for the bias analysis when BMI was analyzed as a continuous variable. BMI = body mass index, SE = standard error.

Discussion

4

As shown in a systematic analysis,[[52]] obesity has become a major global health challenge because of the increasing prevalence of obesity worldwide. From 1980 to 2013, the proportion of overweight and obese people increased to 36.9% for men and 38.0% for women. Consequently, increased morbidity and decreased life expectancy were also observed in the obese.[[53]] Obesity has also been observed to have detrimental effects on multiple eye diseases such as glaucoma,[[54]] late age-related maculopathy,[[55]] and cataracts.[[56]] However, although an increasing number of epidemiologic studies have been performed to analyze the association between BMI and DR, the results are still inclusive. To our knowledge, this was the first meta-analysis to evaluate the association between BMI and DR. In our meta-analysis, neither being overweight nor obesity conferred an increased risk of DR. This was consistent with the previous studies[[57]] where BMI was analyzed as a continuous variable. Notably, significant heterogeneity was observed in our analysis, which may be attributed to differences in study design, participant characteristics, and race or ethnicity, suggesting that our results should be treated with great caution.

To date, very few mechanisms have accounted for the neutral association between BMI and DR. Perhaps obesity has both protective and adverse effects on the risk of DR. Elevated BMI may confer a protective effect on DR through many ways. First, increased C-peptide levels were found in higher BMI individuals,[[58]] which could reduce the risk of DR.[[59]] Moreover, a higher BMI may be a reflection of better glycemic control or shorter diabetes duration. Obese individuals were also more vulnerable to suffer from comorbid conditions; consequently, aggressive treatments have been taken, and reduced the development of DR. In contrast, a higher BMI may have adverse effects on DR. First, an elevated BMI is often correlated with hypertension and dyslipidemia, both of which are risk factors for DR.[[1]] Additionally, hyperleptinemia in obese individuals[[60]] may increase blood pressure and oxidative stress levels, which may partly be responsible for the development of DR. Moreover, higher vascular endothelial growth factor levels were observed in obese individuals,[[61]] which has been shown to be involved in the pathogenesis of proliferative DR.[[62]] We hypothesize that the neutral effects of BMI on DR may counteract its adverse and protective effects.

In contrast to BMI, which is an index for measuring generalized obesity, WHR is used to assess abdominal obesity. There may be some differences in the associations between WHR or BMI and DR. A study[[27]] evaluating the risk of DR in an obese population based on BMI and WHR showed an increased risk in the abdominal obesity group but not in the generalized obesity group. The mechanisms underlying the detrimental WHR-DR association were not defined; however, the high levels of inflammation[[63]] and insulin resistance[[64]] in the abdominal area of obese people may be responsible for the development of DR.

Limitations

4.1

There were several limitations in our meta-analysis, so the results should be interpreted with great caution. First, most of the studies we included were cross-sectional; thus, a causal relationship could not be conferred. Second, BMI is not an accurate parameter to reflect body adiposity since it also includes bone mass and muscle. For example, low BMI individuals may have a higher WC or metabolically obese normal weight.[[65]] Third, significant heterogeneity existed between the studies. Regretfully, we failed to explore the source of heterogeneity because of the limited number of included studies. Fourth, several studies included in this meta-analysis evaluated the association between BMI and DR without differentiating the types of diabetes; therefore, we could not separately evaluate the effects of BMI on DR in patients with type 1 or type 2 diabetes.

Conclusions

5

Our meta-analysis demonstrated that elevated BMI did not increase the risk of DR. However, since being overweight and obesity are risk factors for multiple diseases, it is still imperative to maintain a healthy weight. Notably, since BMI is an index to assess generalized obesity, other anthropometric measurement indexes (e.g., WHR and WC) should also be used to explore the association between obesity and DR. Furthermore, longitudinal studies based on different anthropometric measurement indexes are warranted to determine the association between being overweight or obese and DR.

Acknowledgments

We gratefully thank Z-WG (Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330000, China) for helping us design the search strategy.

References

  1. JW YauSL RogersR KawasakiGlobal prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012;35:556–64.22301125
  2. IM StrattonEM KohnerSJ AldingtonUKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia2001;44:156–63.11270671
  3. F Ismail-BeigiT CravenMA BanerjiEffect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet2010;376:419–30.20594588
  4. JW BeulensA PatelJR VingerlingEffects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia2009;52:2027–36.19633827
  5. MH CriquiMR KlauberE Barrett-ConnorAdjustment for obesity in studies of cardiovascular disease. Am J Epidemiol1982;116:685–91.7137155
  6. W LuczynskiA SzypowskaA Bossowski[Overweight, obesity and metabolic syndrome in children with type 1 diabetes melllitus]. Pediatr Endocrinol Diabetes Metab2010;16:83–8.20813084
  7. LS LimES TaiP MitchellC-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci2010;51:4458–63.20805569
  8. DA MaberleyW KingAF CruessRisk factors for diabetic retinopathy in the Cree of James Bay. Ophthalmic Epidemiol2002;9:153–67.12045883
  9. HT NguyenSD LuzioJ DolbenDominant risk factors for retinopathy at clinical diagnosis in patients with type II diabetes mellitus. J Diabetes Complications1996;10:211–9.8835921
  10. A ArakiH ItoA HattoriRisk factors for development of retinopathy in elderly Japanese patients with diabetes mellitus. Diabetes Care1993;16:1184–6.8375248
  11. MR ManaviatM RashidiM Afkhami-ArdekaniFour years incidence of diabetic retinopathy and effective factors on its progression in type II diabetes. Eur J Ophthalmol2008;18:572–7.18609477
  12. A BenerF Al-LaftahAO Al-HamaqA study of diabetes complications in an endogamous population: an emerging public health burden. Diabetes Metab Syndr2014;8:108–14.24907176
  13. VC LimaGC CavalieriMC LimaRisk factors for diabetic retinopathy: a case-control study. Int J Retina Vitreous2016;2:21.27847639
  14. D KatusicM TomicT JukicObesity—a risk factor for diabetic retinopathy in type 2 diabetes?Coll Antropol2005;29(suppl 1):47–50.16193676
  15. S KastelanM TomicAA GverovicBody mass index: a risk factor for retinopathy in type 2 diabetic patients. Mediators Inflamm2013;2013:436329.24347825
  16. DF StroupJA BerlinSC MortonMeta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA2000;283:2008–12.10789670
  17. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser2000;894:1–253.
  18. GM van DijkM ManevaV ColpaniThe association between vasomotor symptoms and metabolic health in peri- and postmenopausal women: a systematic review. Maturitas2015;80:140–7.25532993
  19. G. Wells SBOC. The Newcastle Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available: www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December 20, 2016, 2014.
  20. E KontopantelisD ReevesPerformance of statistical methods for meta-analysis when true study effects are non-normally distributed: a simulation study. Stat Methods Med Res2012;21:409–26.21148194
  21. C PangL JiaS JiangDetermination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study. Diabetes Metab Res Rev2012;28:276–83.22139892
  22. R RamanPK RaniP GnanamoorthyAssociation of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8). Acta Diabetol2010;47:209–15.
  23. M JanghorbaniM AminiH GhanbariIncidence of and risk factors for diabetic retinopathy in Isfahan, Iran. Ophthalmic Epidemiol2003;10:81–95.12660857
  24. HA van LeidenJM DekkerAC MollBlood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care2002;25:1320–5.12145228
  25. GK DowseAR HumphreyVR CollinsPrevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol1998;147:448–57.9525531
  26. RE ManC SabanayagamPP ChiangDifferential association of generalized and abdominal obesity with diabetic retinopathy in Asian patients with type 2 diabetes. JAMA Ophthalmol2016;134:251–7.26720805
  27. D RooneyWK LyeG TanBody mass index and retinopathy in Asian populations with diabetes mellitus. Acta Diabetol2015;52:73–80.24880522
  28. J LuX HouL ZhangAssociation between body mass index and diabetic retinopathy in Chinese patients with type 2 diabetes. Acta Diabetol2015;52:701–8.25604042
  29. M DiraniJ XieE FenwickAre obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci2011;52:4416–21.21482643
  30. KR AhmedMN KarimMS BukhtRisk factors of diabetic retinopathy in Bangladeshi type 2 diabetic patients. Diabetes Metab Syndr2011;5:196–200.25572762
  31. E Martin-MerinoJ FortunyE Rivero-FerrerRisk factors for diabetic retinopathy in people with Type 2 diabetes: A case-control study in a UK primary care setting. Prim Care Diabetes2016;10:300–8.26860550
  32. EM WebbP RheederP RouxScreening in primary care for diabetic retinopathy, maculopathy and visual loss in South Africa. Ophthalmologica2016;235:141–9.26959502
  33. F Azizi-SoleimanM Heidari-BeniG AmblerIranian risk model as a predictive tool for retinopathy in patients with type 2 diabetes. Can J Diabetes2015;39:358–63.25837808
  34. A KajiwaraH MiyagawaJ SaruwatariGender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: a clinic-based retrospective longitudinal study. Diabetes Res Clin Pract2014;103:e7–10.24503044
  35. M TomicS LjubicS KastelanInflammation, haemostatic disturbance, and obesity: possible link to pathogenesis of diabetic retinopathy in type 2 diabetes. Mediators Inflamm2013;2013:818671.24363502
  36. S LimKM KimMJ KimThe association of maximum body weight on the development of type 2 diabetes and microvascular complications: MAXWEL study. PLoS One2013;8:e80525.24324607
  37. X LiZ WangPrevalence and incidence of retinopathy in elderly diabetic patients receiving early diagnosis and treatment. Exp Ther Med2013;5:1393–6.23737887
  38. Y ZhengEL LamoureuxR LavanyaPrevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. Ophthalmology2012;119:2119–24.22709419
  39. R KawasakiS TanakaS TanakaIncidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia2011;54:2288–94.21630126
  40. Y YoshidaR HaguraY HaraRisk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diabetes Res Clin Pract2001;51:195–203.11269892
  41. P MitchellW SmithJJ WangPrevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology1998;105:406–11.9499768
  42. VR CollinsGK DowseWE PlehweHigh prevalence of diabetic retinopathy and nephropathy in Polynesians of Western Samoa. Diabetes Care1995;18:1140–9.7587849
  43. A OkumuraH Unoki-KubotaN Yoshida-HataReduced serum level of leukocyte cell-derived chemotaxin 2 is associated with the presence of diabetic retinopathy. Clin Chim Acta2016;463:145–9.27816666
  44. R SekiokaM TanakaT NishimuraSerum total bilirubin concentration is negatively associated with increasing severity of retinopathy in patients with type 2 diabetes mellitus. J Diabetes Complications2015;29:218–21.25536865
  45. PD LoprinziConcurrent healthy behavior adoption and diabetic retinopathy in the United States. Prev Med Rep2015;2:591–4.26844123
  46. G GarbergM Lovestam-AdrianS NasicThe prognosis of diabetic retinopathy in patients with type 2 diabetes since 1996-1998: the Skaraborg Diabetes Register. Int Ophthalmol2015;35:503–11.25143261
  47. D JeeWK LeeS KangPrevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008–2011. Invest Ophthalmol Vis Sci2013;54:6827–33.24065813
  48. J XuWB WeiMX YuanPrevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina2012;32:322–9.21886023
  49. TY WongN CheungWT TayPrevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology2008;115:1869–75.18584872
  50. T FujisawaH IkegamiE YamatoAssociation of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in Type 2 diabetes mellitus. Diabet Med1999;16:522–6.10391402
  51. M RemaM PonnaiyaV MohanPrevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes centre in southern India. Diabetes Res Clin Pract1996;34:29–36.8968688
  52. M NgT FlemingM RobinsonGlobal, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2014;384:766–81.24880830
  53. KR FontaineDT ReddenC WangYears of life lost due to obesity. JAMA2003;289:187–93.12517229
  54. B BengtssonA HeijlA long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma2005;14:135–8.15741815
  55. C DelcourtF MichelA ColvezAssociations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol2001;8:237–49.11471092
  56. J YeLX LouJJ HeBody mass index and risk of age-related cataract: a meta-analysis of prospective cohort studies. PLoS One2014;9:e89923.24587127
  57. J WangRY ZhangRP ChenPrevalence and risk factors for diabetic retinopathy in a high-risk Chinese population. BMC Public Health2013;13:633.23826664
  58. J AhrenB AhrenN WierupIncreased beta-cell volume in mice fed a high-fat diet: a dynamic study over 12 months. Islets2010;2:353–6.21099337
  59. X CaiX HanS ZhangAge at diagnosis and C-peptide level are associated with diabetic retinopathy in Chinese. PLoS One2014;9:e91174.24614131
  60. RV ConsidineMK SinhaML HeimanSerum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med1996;334:292–5.8532024
  61. S Miyazawa-HoshimotoK TakahashiH BujoElevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia2003;46:1483–8.14534780
  62. LP AielloRL AveryPG ArriggVascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med1994;331:1480–7.7526212
  63. DB PanagiotakosC PitsavosM YannakouliaThe implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis2005;183:308–15.16285994
  64. WY FujimotoSL AbbateSE KahnThe visceral adiposity syndrome in Japanese–American men. Obes Res1994;2:364–71.16353583
  65. N RudermanD ChisholmX Pi-SunyerThe metabolically obese, normal-weight individual revisited. Diabetes1998;47:699–713.9588440
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5459694/fullTextXML. The license for the article is Creative Commons Attribution-NonCommercial 4.0 License. The main subject has been identified as diabetic retinopathy.